Druggable transcriptomic pathways revealed in Parkinson's patient-derived midbrain neurons

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Parkinson's disease (PD) involves progressive degeneration of midbrain substantia nigra neurons, driven by complex genetic factors.
• Current understanding of PD pathophysiology largely stems from late-stage postmortem brain studies, lacking insights into early molecular events.
• There is a critical need to identify molecular changes preceding neuronal loss to develop effective therapeutics.

Purpose of the Study:

• To investigate the early molecular dysregulation in Parkinson's disease using reprogrammed midbrain neurons from patients.
• To establish an integrated analysis pipeline for transcriptomic data from diverse reprogramming and sequencing methods.
• To identify potential therapeutic targets for slowing PD progression before irreversible neuronal damage.

Main Methods:

• Reprogramming skin cells from 42 individuals (PD patients and controls) into midbrain neurons in vitro.
• Developing an integrated analysis pipeline for diverse RNA-seq datasets (bulk, single-cell, Patch-seq) and reprogramming strategies.
• Utilizing patch-clamping to confirm synaptic function and analyzing gene-chemical interactions.

Main Results:

• The PD patient transcriptome showed enrichment for genes linked to PD phenotypes, locomotion, bradykinesia, and rigidity.
• Key dysregulated pathways included synaptic transmission, metabolism, intracellular trafficking, neural morphogenesis, and cellular stress/immune responses.
• Synaptic impairment was confirmed, and pesticides/endoplasmic reticulum stressors were identified as significant gene-chemical interactions.

Conclusions:

• This study identifies crucial early transcriptomic pathways in Parkinson's disease, offering potential therapeutic targets.
• Reprogrammed patient neurons provide a valuable model for studying preclinical PD pathophysiology.
• The findings support the development of therapies aimed at intervening before substantial neuronal loss.